Cumulative hazard data from the date of the first statin purchase until the date of major cardiovascular event or censoring and stratified according to eligibility for the HPS(DM) trial.
Posterior Probabilities and Protected Exceedance Probabilities obtained from Bayesian Model Comparison of three alternative Response Models described in Marshall et al. Data are drug-group x respon
Supplementary tables 1 and 2 containing statistical analysis for the manuscript titled " Mitoquinone mesylate attenuates pathologic features of obese allergic asthma in mice".
This dataset was generated in an in vivo study during which the potential anti-inflammatory effects of tobacco alkaloids were explored in the full human immune system Hu-Mouse model combined with UC m
These tables summarize the reported literature on the use of systemic Rituximab in patients with primary cutaneous folicular center cell lymphomas (PCFCL) and primary cutaneous marginal zone lymphomas